Teva asthma treatment receives positive CHMP opinion

Teva Pharmaceutical's DuoResp Spiromax treatment has moved one step closer to European Commission (EC) approval after it was granted a positive opinion recommending market authorisation for the inhalation powder.

It has been indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD) by the European Medicines Agency's Committee for Medicinal Products for Human Use.

Following the recommendation, the EC is now expected make a final approval decision within the next few months.

The Spiromax inhaler has been designed to utilise breath-accentuated technology to provide a consistent dose of the medicine, whether it is the first time it is being used or the last. 

Michael Hayden, Teva's president of global research and development and chief scientific officer, said: "The Spiromax inhaler is an important addition to our respiratory portfolio and supports our strategy to become a leading presence … with a robust and differentiated pipeline, projected to be a multi-billion dollar franchise by the end of the decade."